HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Platelet factor V deficiency (factor V Quebec) — Clinical Guidelines

Overview

Platelet factor V deficiency, also known as factor V Quebec, is a rare bleeding disorder characterized by impaired platelet function and coagulation due to a deficiency in factor V localized within platelets. It often presents with a bleeding tendency and poor wound healing 5.

Diagnosis

Clinical Presentation: Bleeding tendency, poor wound healing, and possibly associated conditions like Klippel-Weber disease 5.

Laboratory Tests:

- Factor V activity assay showing reduced levels (e.g., <10%) 5. - Platelet function tests revealing dysfunction (e.g., decreased clot retraction, reduced thrombelastogram amplitude) 5. - Additional tests for cryofibrinogenemia and chronic disseminated intravascular coagulation (DIC) may be relevant 5.

Management

First-Line Treatments:

- Replacement Therapy: Use of solvent-detergent plasma for replacement therapy, particularly in pregnancy 2. - Fresh Frozen Plasma (FFP): High doses may be required in severe cases, such as postoperative hemorrhage 8.

Adjunctive Treatments:

- Immunosuppressive Therapy: In cases with acquired inhibitors, aggressive treatment with prednisone, rituximab, cyclophosphamide, immunoglobulin, and immunoadsorption may be considered 1. - Immune Tolerance Induction: Strategies to induce immune tolerance may be explored in refractory cases 1.

Special Populations

Pregnancy: Solvent-detergent plasma can be effectively used for managing factor V deficiency during pregnancy 2.

Comorbidities: Patients may have associated conditions like Klippel-Weber disease, platelet dysfunction, and cryofibrinogenemia, requiring comprehensive management 5.

Key Recommendations

Use solvent-detergent plasma for replacement therapy in pregnant patients with factor V deficiency (Evidence: Moderate 2).

Initiate aggressive immunosuppressive therapy for acquired inhibitors, including prednisone, rituximab, and immunoadsorption (Evidence: Weak 1).

Monitor and manage associated comorbidities such as Klippel-Weber disease and platelet dysfunction (Evidence: Expert opinion 5).

References

1 Boehlen F, Casini A, Chizzolini C, Mansouri B, Kohler HP, Schroeder V et al.. Acquired factor XIII deficiency: a therapeutic challenge. Thrombosis and haemostasis 2013. link 2 O'Connell MP, Eogan M, Murphy KM, White B, Keane DP, O'Donnell J. Solvent-detergent plasma as replacement therapy in a pregnant patient with factor V deficiency. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2004. link 3 Finn PJ, Ferguson IA, Renton FJ, Rush RA. Nerve growth factor immunohistochemistry and biological activity in the rat iris. Journal of neurocytology 1986. link 4 Coggan M, Board PG. A fluorescent spot test for coagulation factor XIII. Analytical biochemistry 1984. link90105-2) 5 Endo Y, Takahashi K, Mamiya S, Satoh M, Matsuda M. Factor XIII deficiency associated with Klippel-Weber disease, platelet dysfunction and cryofibrinogenemia. Acta haematologica 1983. link 6 Pearson RW, Triplett DA. Factor XI assay results in the CAP survey (1981). American journal of clinical pathology 1982. link 7 Perhavec JC, Goldberg JS. Management of a patient with Factor VII deficiency. Oral surgery, oral medicine, and oral pathology 1980. link90324-2) 8 Gilmore WC, Doku HC. Factor XI deficiency resulting in severe postoperative hemorrhage after odontectomy. Journal of oral surgery (American Dental Association : 1965) 1979. link

Platelet factor V deficiency (factor V Quebec)